Adaptimmune and Universal Cells in T-cell therapy collaboration
1 December 2015 | By Victoria White
With Universal Cells’ proprietary gene editing technology, Adaptimmune intends to develop affinity enhanced donor T-cells...
List view / Grid view
1 December 2015 | By Victoria White
With Universal Cells’ proprietary gene editing technology, Adaptimmune intends to develop affinity enhanced donor T-cells...
26 October 2015 | By Victoria White
The US 9,181,527 Celyad Allogeneic Patent significantly strengthens Celyad’s patent portfolio in the CAR T-Cell field...
8 October 2015 | By Victoria White
NKTR-214 is a CD122-biased immune-stimulatory cytokine that is designed to stimulate the expansion and maintenance of CD8-positive effector T-cells...
10 July 2015 | By Victoria White
apceth is to partner with the University of Cologne to combine technologies and expertise, on the development of immunotherapies for solid tumours...
9 July 2015 | By Victoria White
Scientists have shown that didehydro-Cortistatin A reduces residual levels of HIV virus from dormant cells, establishing a near-permanent state of latency...
30 June 2015 | By Victoria White
Celgene and Juno Therapeutics have entered into a global collaboration for the development and commercialisation of immunotherapies...
4 June 2015 | By Victoria White
When the T cells of your immune system are forced to deal over time with cancer or a chronic infection, they can develop "T cell exhaustion"...
Immune checkpoint inhibitory antibodies have provided a great conceptual change in the field of immune-oncology. Rather than targeting the tumour directly, these novel drugs are aimed at preventing the interactions between the tumour and the immune system, which the cancer exploits to evade immune recognition...